Voyager Therapeutics is trading $2.03, down 5.58%, amid broader-market weakness; no clear company-specific announcement explaining the October 14 decline was found. - Hotter-than-expected September inflation boosted rate-hike concerns. Reuters reported U.S. indexes fell as rate expectations rose and Treasury yields climbed, weighing on growth-sensitive shares. - The supplied market context showed the S&P 500 down 1.27% and Nasdaq down 1.98%; this supports broader-market pressure but does not confirm a direct cause.